Acylated glucagon analogues

US10457714B2 · kind B2 · utility

Assignee

• Zealand Pharma A/S · DK

Inventors

• Ditte Riber · Copenhagen, DK
• Jakob Lind Tolborg · Avenue Madeleine, DK
• Dieter Hamprecht · Verona, IT
• Wolfgang Rist · Ingelheim am Rhein, DE

Key dates

• Filing date: Dec 22, 2017
• Grant date: Oct 29, 2019
• Expiry date: Dec 22, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.